The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill
A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.
The review does not include North America, the healthcare giant said.
CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
FDA panel votes in favor of Vertex's combination cystic fibrosis drug; MannKind blames marketing on slow Afrezza sales; Orexigen draws ire after Contrave study terminated
The government agency said discontinuing Namenda IR before generic competition enters the market could cost Medicare and its beneficiaries billions over the next decade.
Value is a concept that concerns all healthcare stakeholders.
While the FDA is not required to follow the panel's recommendation, the agency's final decision on Orkambi is crucial to Vertex's future.
A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug
Spurred by consolidation, the life sciences industry spent more money on acquisitions in the first quarter than it did in all of 2014 combined.
Amgen raises price of Enbrel by 10%; pharma companies appear to raise diabetes drug prices in tandem; Alexion agrees to buy rare-disease drugmaker for $8.4 billion
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
The drugmaker brought in Anne Whitaker, citing her experience in the gastrointestinal space.
FDA approves generic Abilify; Mylan raises its offer to buy Perrigo; drugmakers are racing to develop drugs for celiac disease.
Newly approved Opdivo added $40 million to the quarter's product sales, which rose 8.9% compared to the year-earlier period.
PCSK9 antibodies reduced overall mortality and lowered LDL cholesterol levels in more than 10,000 patients in Phase-II/III clinical trials.
More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market
The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.
An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo
The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.
Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.
Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas
Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.
A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.
Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.
FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad
The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.
An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.